Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. [1][2][3][4]

Entinostat is a selective, oral, once-weekly, class I HDAC inhibitor that has been studied in multiple solid tumors in combination with hormone therapy and several approved PD-1/PD-L1 …

Effects of the HDAC inhibitor Entinostat (MS-275) have been examined in human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary acute myelogenous …

Entinostat is defined as a histone deacetylase inhibitor, specifically a 2-aminophenyl-benzamide, that selectively inhibits class I enzymes HDAC1 to HDAC3, and is considered a promising …

This article provides an overview of the chemistry, pharmacokinetics/pharmacodynamics and available clinical data for entinostat with a focus on advanced breast cancer.

entinostat A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene …

Entinostat, a histone deacetylase (HDAC) inhibitor, is being extensively studied in clinical trials for its potential in treating various types of cancer. This article explores the ongoing research on …

Oct 20, 2016 · Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the …

Mar 6, 2025 · Entinostat is an orally available small‐molecule drug candidate that has captured considerable attention due to its unique ability to modulate the epigenetic landscape required …

Feb 14, 2024 · In this breast expansion cohort of our multicenter phase I clinical trial, the combination of entinostat + nivolumab + ipilimumab demonstrates promising efficacy in …